Leo Pharma closely followed by Pfizer and Abbvie with FDA atopic eczema approvals
Only a few weeks after the FDA approved Leo Pharma's Adbry for atopic eczema, Pfizer and Abbvie are cleared with drugs in the same indication.
by ULRICH QUISTGAARD, translated by daniel pedersen
A race has broken out on the atopic eczema market in the US. While Danish pharmaceutical firm Leo Pharma leads among three new contenders, having had its candidate approved by the US Food and Drug Administration (FDA) around New Year's, it will soon be followed by two other treatments.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
